A TWEAK in lupus nephritis

Clinical Immunology

Volumn 145, Issue 2, 2012, Pages 139-140

  Crispín, José C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CHEMOKINE; CYTOKINE; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE MOLECULE 14; INTERCELLULAR ADHESION MOLECULE 1; KALLIKREIN; KI 67 ANTIGEN; TUMOR NECROSIS FACTOR RELATED WEAK INDUCER OF APOPTOSIS PROTEIN; TUMOR NECROSIS FACTOR RELATED WEAK INDUCER OF APOPTOSIS PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOKINE PRODUCTION; EDITORIAL; GLOMERULONEPHRITIS; HUMAN; HUMORAL IMMUNITY; IMMUNE COMPLEX DEPOSITION; INFLAMMATION; INNATE IMMUNITY; KIDNEY FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEINURIA; RENAL PROTECTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES; GLOMERULONEPHRITIS; KIDNEY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 84866718566     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.09.002     Document Type: Editorial

References (19)

1. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011, 365:2110-2121.
2. Gonzalez-Crespo M.R., Lopez-Fernandez J.I., Usera G., Poveda M.J., Gomez-Reino J.J. Outcome of silent lupus nephritis. Semin. Arthritis Rheum. 1996, 26:468-476.
3. Valente de Almeida R., Rocha de Carvalho J.G., de Azevedo V.F., et al. Microalbuminuria and renal morphology in the evaluation of subclinical lupus nephritis. Clin. Nephrol. 1999, 52:218-229.
4. Rovin B.H., Stillman I.E. Kidney. Systemic Lupus Erythematosus 2011, 769-814. Elsevier, Amsterdam. Fifth edition. R.G. Lahita, G.C. Tsokos, J. Buyon, T. Koike (Eds.).
5. Liu K., Li Q.Z., Delgado-Vega A.M., et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J. Clin. Invest. 2009, 119:911-923.
6. Juang Y.T., Wang Y., Solomou E.E., et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 2005, 115:996-1005.
7. T. Koga, K. Ichinose, M. Mizui, J.C. Crispin, G.C. Tsokos, Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus, J. Immunol. 189, http://dx.doi.org/10.4049/jimmunol.1201785.
8. Ichinose K., Rauen T., Juang Y.T., et al. Cutting edge: calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J. Immunol. 2011, 187:5500-5504.
9. Maecker H., Varfolomeev E., Kischkel F., et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005, 123:931-944.
10. Wiley S.R., Cassiano L., Lofton T., et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15:837-846.
11. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 2008, 7:411-425.
12. Burkly L.C., Michaelson J.S., Zheng T.S. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol. Rev. 2011, 244:99-114.
13. van Kuijk A.W., Wijbrandts C.A., Vinkenoog M., Zheng T.S., Reedquist K.A., Tak P.P. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann. Rheum. Dis. 2010, 69:301-304.
14. Serafini B., Magliozzi R., Rosicarelli B., Reynolds R., Zheng T.S., Aloisi F. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J. Neuropathol. Exp. Neurol. 2008, 67:1137-1148.
15. Lu J., Kwan B.C., Lai F.M., et al. Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology (Carlton) 2011, 16:426-432.
16. Schwartz N., Rubinstein T., Burkly L.C., et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res. Ther. 2009, 11:R143.
17. Zhao Z., Burkly L.C., Campbell S., et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 2007, 179:7949-7958.
18. Xia Y., Campbell S.R., Broder A., et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin. Immunol. 2012, 145:108-121.
19. Fu Y., Du Y., Mohan C. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin. Immunol. 2007, 124:109-118.